JPH07500355A - 2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸の誘導体の硝酸エステルおよびその製造法 - Google Patents
2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸の誘導体の硝酸エステルおよびその製造法Info
- Publication number
- JPH07500355A JPH07500355A JP6505826A JP50582694A JPH07500355A JP H07500355 A JPH07500355 A JP H07500355A JP 6505826 A JP6505826 A JP 6505826A JP 50582694 A JP50582694 A JP 50582694A JP H07500355 A JPH07500355 A JP H07500355A
- Authority
- JP
- Japan
- Prior art keywords
- halo
- phenylamino
- phenylacetic acid
- derivative
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 title claims description 52
- -1 Nitric acid ester Chemical class 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 229910017604 nitric acid Inorganic materials 0.000 title description 4
- 229960003424 phenylacetic acid Drugs 0.000 claims description 23
- 239000003279 phenylacetic acid Substances 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000000460 chlorine Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 229910052801 chlorine Inorganic materials 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 12
- 239000000178 monomer Substances 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical group 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 150000008064 anhydrides Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 230000000802 nitrating effect Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 3
- 150000001263 acyl chlorides Chemical class 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 150000001218 Thorium Chemical class 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- ZGUNAGUHMKGQNY-UHFFFAOYSA-N alpha-phenylglycine Chemical class OC(=O)C(N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-UHFFFAOYSA-N 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 5
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 claims 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 229910020667 PBr3 Inorganic materials 0.000 claims 1
- 241000577218 Phenes Species 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 229910052740 iodine Chemical group 0.000 claims 1
- 239000011630 iodine Chemical group 0.000 claims 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 4
- 229960001123 epoprostenol Drugs 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003989 endothelium vascular Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049953 phenylacetate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 231100000456 subacute toxicity Toxicity 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- LXQJQOOPNULMTQ-UHFFFAOYSA-N 4-(2,6-dichloroanilino)-6-hydroxy-2-phenylhexanamide Chemical compound ClC1=C(C(=CC=C1)Cl)NC(CC(C(=O)N)C1=CC=CC=C1)CCO LXQJQOOPNULMTQ-UHFFFAOYSA-N 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (9)
- 1.2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸の誘導体であって 、下記の一般式▲数式、化学式、表等があります▼(I)(式中、 AおよびBは、水素、線状のまたは分岐した置換または非置換アルキル鎖の中か ら選ばれ、Xは塩素および臭素から選択されるハロゲンであり、 Yは酸素、NH、NR1から選択され、ここで、R1は線状または分岐したアル キル基であり、nは1〜10である)を有することを特徴とする誘導体。
- 2.Xが塩素であり、AおよびBが水素であり、Yが酸素であり、nが4である 、請求の範囲第1項に記載の2−(2,6−ジ−ハロ−フェニルアミノ)フェニ ル酢酸の誘導体。
- 3.Xが塩素であり、AおよびBが水素であり、Yが酸素であり、nが2である 、請求の範囲第1項に記載の2−(2,6−ジ−ハロ−フェニルアミノ)フェニ ル酢酸の誘導体。
- 4.Xが塩素であり、AおよびBが水素であり、YがNHであり、nが4である 、請求の範囲第1項に記載の2−(2′6−ジ−ハロ−フェニルアミノ)フェニ ル酢酸の誘導体。
- 5.抗炎症薬として薬学の分野で利用可能である、請求の範囲第1項に記載の2 −(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸の誘導体。
- 6.リウマチ性疾患の治療、免疫性疾患および中度の程度の苦痛を伴う症状の治 療に利用可能である、請求の範囲第1項に記載の2−(2,6−ジ−ハロ−フェ ニルアミノ)フェニル酢酸の誘導体。
- 7.循環器系、心筋および脳虚血の疾患、および動脈血栓の治療に利用可能であ る、請求の範囲第1項に記載の2−(2,6−ジ−ハロ−フェニルアミノ)フェ ニル酢酸の誘導体。
- 8.下記の一般式 ▲数式、化学式、表等があります▼(I)(式中、 AおよびBは、水素、線状および分岐した置換および非置換アルキル鎖の中から 選択され、Xは塩素および臭素から選択されるハロゲンであり、 Yは酸素、NH、NR1から選択され、ここで、R1は線状または分岐したアル キル基であり、nは1〜10である)を有する2−(2,6−ジ−ハロ−フェニ ルアミノ)フェニル酢酸の誘導体の製造法であって、 2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸のまたはカルボキシル 基が官能化された2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸のナ トリウム塩と、下記の一般式 ▲数式、化学式、表等があります▼(IV)(式中、 R4は塩素、臭素、NHRから選択され、ここでRは水素または線状若しくは分 岐したアルキル鎮であり、AおよびBは水素、線状若しくは分岐した置換または 非置換アルキル鎖であり、R3は塩素、臭素およびヨウ素から選択され、 nは1〜10であり、 2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸のカルボキシル基がア シル塩化物、無水物などとして官能化されている)を有する化合物との反応であ って、この方法で対応するモノマーエステルまたは対応するアミドを得る反応と 、 前記モノマーエステルまたは前記アミドとAgNO3などのニトロ化剤との反応 であって、この方法で2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸 の誘導体の硝酸エステル(I)を得る反応、の段階を含むことを特徴とする方法 。
- 9.下記の一般式 ▲数式、化学式、表等があります▼(I)(式中、 AおよびBは、水素、線状または分岐した置換または非置換アルキル鎖の中から 選択され、Xは塩素および臭素カら選択されるハロゲンであり、 Yは酸素、NH、NR1から選択され、ここで、R1は線状または分岐したアル キル基であり、nは1〜10である)を有する2−(2,6−ジ−ハロ−フェニ ルアミノ)フェニル酢酸の誘導体の製造法であって、2−(2,6−ジ−ハロ− フェニルアミノ)フェニル酢酸のまたはカルボキシル基が官能化された2−(2 ,6−ジ−ハロ−フェニルアミノ)フェニル酢酸のナトリウム塩と、下記の一般 式 ▲数式、化学式、表等があります▼(V)(式中、 R4は塩素、臭素、NHRから選択され、ここでRは水素または線状若しくは分 岐したアルキル鎖であり、AおよびBは水素、線状若しくは分岐した置換または 非置換アルキル鎖であり、nは1〜10であり、2−(2,6−ジ−ハロ−フェ ニルアミノ)フェニル酢酸のカルボキシル基がアシル塩化物、無水物などとして 官能化されている)を有する化合物との反応であって、この方法で対応するモノ マーエステルまたは対応するアミドを得る反応と、 前記モノマーエステルまたは前記アミドとハロゲン化化合物、たとえばPBr3 などとの反応であって、この方法で末端ハロゲン基の存在を特徴とする前記モノ マーエステルまたは前記アミドを得る反応と、末端ハロゲン基の存在を特徴とす る前記モノマーエステルまたは前記アミドとニトロ化剤、たとえばAgNO3な どとの反応であって、この方法で2−(2,6−ジ−ハロ−フェニルアミン)フ ェニル酢酸の誘導体の硝酸エステル(I)を得る反応、 の段階を含むことを特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT92A002006 | 1992-08-20 | ||
ITMI922006A IT1256345B (it) | 1992-08-20 | 1992-08-20 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione |
PCT/EP1993/001906 WO1994004484A1 (en) | 1992-08-20 | 1993-07-20 | Nitric esters of derivatives of the 2-(2,6-di-halophenylamino)phenylacetic acid and process for their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07500355A true JPH07500355A (ja) | 1995-01-12 |
JP3231042B2 JP3231042B2 (ja) | 2001-11-19 |
Family
ID=11363881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50582694A Expired - Fee Related JP3231042B2 (ja) | 1992-08-20 | 1993-07-20 | 2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸の誘導体の硝酸エステルおよびその製造法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US5597847A (ja) |
EP (1) | EP0609415B1 (ja) |
JP (1) | JP3231042B2 (ja) |
KR (1) | KR100269727B1 (ja) |
AT (1) | ATE143941T1 (ja) |
CA (1) | CA2120942C (ja) |
DE (1) | DE69305322T2 (ja) |
DK (1) | DK0609415T3 (ja) |
ES (1) | ES2093979T3 (ja) |
GR (1) | GR3021404T3 (ja) |
HK (1) | HK1006967A1 (ja) |
IT (1) | IT1256345B (ja) |
RU (1) | RU2109009C1 (ja) |
UA (1) | UA39172C2 (ja) |
WO (1) | WO1994004484A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541236A (ja) * | 1999-04-13 | 2002-12-03 | ニコックス エス エイ | 医薬化合物 |
JP2003500442A (ja) * | 1999-06-01 | 2003-01-07 | アストラゼネカ・アクチエボラーグ | 化合物の抗菌剤としての新規な使用 |
JP2003515526A (ja) * | 1999-08-12 | 2003-05-07 | ニコックス エス エイ | 医薬化合物 |
JP2003525894A (ja) * | 2000-03-08 | 2003-09-02 | アストラゼネカ・アクチエボラーグ | 新規な自己乳化性薬物送達系 |
JP2005504788A (ja) * | 2001-09-07 | 2005-02-17 | アストラゼネカ・アクチエボラーグ | 新規な自己乳化薬物送達システム |
JP2010280665A (ja) * | 2002-07-03 | 2010-12-16 | Nicox Sa | ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009831A1 (en) * | 1993-10-06 | 1995-04-13 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation |
CA2190087C (en) * | 1994-05-10 | 2005-08-02 | Piero Del Soldato | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities |
US6043232A (en) * | 1997-07-23 | 2000-03-28 | Nitromed, Inc. | Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs |
US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
ES2092962B1 (es) * | 1995-04-19 | 1997-07-16 | Prodes Sa | Esteres nitricos de derivados del acido 2-(2,6-dihalofenilamino) fenilacetoxiacetico y sus procedimientos de preparacion. |
US5792758A (en) * | 1995-12-08 | 1998-08-11 | G. D. Searle & Co. | Steroid nitrite ester derivatives useful as anti-inflammatory drugs |
SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
US6355680B1 (en) * | 1996-02-20 | 2002-03-12 | Exocell, Inc. | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
IT1282686B1 (it) | 1996-02-26 | 1998-03-31 | Nicox Sa | Composti in grado di ridurre la tossicita' da farmaci |
CA2262788A1 (en) * | 1996-08-16 | 1998-02-26 | Gustavo Enrique Aldoma | Non-ulcerogenic analgesic/anti-inflammatory clonixin derivative |
IT1288123B1 (it) | 1996-09-04 | 1998-09-10 | Nicox Sa | Uso di nitroderivati per l'incontinenza urinaria |
IT1285770B1 (it) | 1996-10-04 | 1998-06-18 | Nicox Sa | Composti corticoidei |
IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
FR2757159B1 (fr) * | 1996-12-12 | 1999-12-17 | Hoechst Marion Roussel Inc | Nouveaux derives nitres analgesiques, anti-inflammatoires et anti-thrombotiques, leur procede de preparation, leur application comme medicaments |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
US6297260B1 (en) | 1998-10-30 | 2001-10-02 | Nitromed, Inc. | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
IT1308633B1 (it) | 1999-03-02 | 2002-01-09 | Nicox Sa | Nitrossiderivati. |
IT1311924B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1312115B1 (it) | 1999-06-24 | 2002-04-04 | Nicox Sa | Composti amorfi e relative composizioni farmaceutiche |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6552078B2 (en) | 1999-10-27 | 2003-04-22 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
US6436990B1 (en) | 1999-10-27 | 2002-08-20 | Nobex Corporation | 6-methoxy-2-naphthylacetic acid prodrugs |
TWI262791B (en) | 1999-10-27 | 2006-10-01 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
JP2003523958A (ja) | 1999-12-23 | 2003-08-12 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−2の阻害剤、組成物ならびに使用法 |
SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
IT1319201B1 (it) * | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per il diabete. |
IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
JP4092203B2 (ja) | 2000-12-21 | 2008-05-28 | ニトロメッド,インク. | 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法 |
ITMI20010985A1 (it) * | 2001-05-15 | 2002-11-15 | Nicox Sa | Farmaci per il morbo di alzheimer |
ITMI20011744A1 (it) * | 2001-08-09 | 2003-02-09 | Nicox Sa | Farmaci per le vasculopatie |
AU2003248642A1 (en) | 2002-06-11 | 2003-12-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
CA2492066A1 (en) | 2002-06-28 | 2004-01-08 | Nitromed, Inc. | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
EP1542972A4 (en) | 2002-07-29 | 2008-01-23 | Nitromed Inc | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITION AND METHOD OF USE |
SE0203093D0 (en) * | 2002-10-18 | 2002-10-18 | Astrazeneca Uk Ltd | New use |
AR042206A1 (es) | 2002-11-26 | 2005-06-15 | Novartis Ag | Acidos fenilaceticos y derivados |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
AR061623A1 (es) | 2006-06-26 | 2008-09-10 | Novartis Ag | Derivados de acido fenilacetico |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3558690A (en) * | 1965-04-08 | 1971-01-26 | Gelgy Chemical Corp | Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation |
DE3407507A1 (de) * | 1984-03-01 | 1985-09-05 | A. Nattermann & Cie GmbH, 5000 Köln | Neue o-(2,6-dichloranilino)-phenylessigsaeureester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
US5021576A (en) * | 1989-10-27 | 1991-06-04 | American Home Products Corporation | 2-Anilino phenylacetic acid derivatives |
-
1992
- 1992-08-20 IT ITMI922006A patent/IT1256345B/it active IP Right Grant
-
1993
- 1993-07-20 WO PCT/EP1993/001906 patent/WO1994004484A1/en active IP Right Grant
- 1993-07-20 EP EP93917596A patent/EP0609415B1/en not_active Expired - Lifetime
- 1993-07-20 CA CA002120942A patent/CA2120942C/en not_active Expired - Fee Related
- 1993-07-20 ES ES93917596T patent/ES2093979T3/es not_active Expired - Lifetime
- 1993-07-20 DE DE69305322T patent/DE69305322T2/de not_active Expired - Lifetime
- 1993-07-20 RU RU94046148A patent/RU2109009C1/ru not_active IP Right Cessation
- 1993-07-20 KR KR1019940701286A patent/KR100269727B1/ko not_active IP Right Cessation
- 1993-07-20 US US08/211,447 patent/US5597847A/en not_active Expired - Lifetime
- 1993-07-20 JP JP50582694A patent/JP3231042B2/ja not_active Expired - Fee Related
- 1993-07-20 DK DK93917596.4T patent/DK0609415T3/da active
- 1993-07-20 AT AT93917596T patent/ATE143941T1/de not_active IP Right Cessation
- 1993-07-20 UA UA94005348A patent/UA39172C2/uk unknown
-
1996
- 1996-10-21 GR GR960402711T patent/GR3021404T3/el unknown
-
1998
- 1998-06-23 HK HK98106190A patent/HK1006967A1/xx not_active IP Right Cessation
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002541236A (ja) * | 1999-04-13 | 2002-12-03 | ニコックス エス エイ | 医薬化合物 |
JP2003500442A (ja) * | 1999-06-01 | 2003-01-07 | アストラゼネカ・アクチエボラーグ | 化合物の抗菌剤としての新規な使用 |
JP4818516B2 (ja) * | 1999-06-01 | 2011-11-16 | アストラゼネカ・アクチエボラーグ | 化合物の抗菌剤としての新規な使用 |
JP2003515526A (ja) * | 1999-08-12 | 2003-05-07 | ニコックス エス エイ | 医薬化合物 |
JP2003525894A (ja) * | 2000-03-08 | 2003-09-02 | アストラゼネカ・アクチエボラーグ | 新規な自己乳化性薬物送達系 |
JP4663197B2 (ja) * | 2000-03-08 | 2011-03-30 | ニコックス・ソシエテ・アノニム | 新規な自己乳化性薬物送達系 |
JP2005504788A (ja) * | 2001-09-07 | 2005-02-17 | アストラゼネカ・アクチエボラーグ | 新規な自己乳化薬物送達システム |
JP4656483B2 (ja) * | 2001-09-07 | 2011-03-23 | ニコックス・ソシエテ・アノニム | 新規な自己乳化薬物送達システム |
JP2010280665A (ja) * | 2002-07-03 | 2010-12-16 | Nicox Sa | ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法 |
Also Published As
Publication number | Publication date |
---|---|
RU2109009C1 (ru) | 1998-04-20 |
DK0609415T3 (da) | 1996-11-18 |
HK1006967A1 (en) | 1999-03-26 |
EP0609415B1 (en) | 1996-10-09 |
US5597847A (en) | 1997-01-28 |
ES2093979T3 (es) | 1997-01-01 |
IT1256345B (it) | 1995-12-01 |
UA39172C2 (uk) | 2001-06-15 |
ATE143941T1 (de) | 1996-10-15 |
WO1994004484A1 (en) | 1994-03-03 |
CA2120942C (en) | 2005-09-27 |
ITMI922006A0 (it) | 1992-08-20 |
EP0609415A1 (en) | 1994-08-10 |
DE69305322T2 (de) | 1997-02-20 |
CA2120942A1 (en) | 1994-03-03 |
GR3021404T3 (en) | 1997-01-31 |
DE69305322D1 (de) | 1996-11-14 |
ITMI922006A1 (it) | 1994-02-20 |
KR100269727B1 (ko) | 2000-10-16 |
JP3231042B2 (ja) | 2001-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07500355A (ja) | 2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸の誘導体の硝酸エステルおよびその製造法 | |
US4182774A (en) | Method of inhibiting blood platelet aggregation with 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof | |
JP3231043B2 (ja) | 薬理活性を有する硝酸エステルおよびその製法 | |
US4443475A (en) | Amides of acyl-carnitines, process for preparing same and pharmaceutical compositions containing such amides | |
JPH09503214A (ja) | 抗炎症活性及び/又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法 | |
CH651561A5 (fr) | Derives des nor-tropane et granatane et leur procede de preparation. | |
CH637927A5 (fr) | Derives de 4-amino-5-alkylsulfonyl ortho-anisamides et leurs procedes de preparation. | |
JPH0211579B2 (ja) | ||
JPS6229566A (ja) | 新規グアニジノメチル安息香酸誘導体 | |
SU1151209A3 (ru) | Способ получени @ -токофериловых эфиров 5-замещенной пиколиновой кислоты | |
EP0286643A1 (en) | PHARMACEUTICALLY ACTIVE DERIVATIVES OF GLUTAMINE AND ASPARAGIC ACIDS. | |
US4000297A (en) | N-p-chlorobenzoyl tryptophane, salts and compositions thereof | |
JPH02124884A (ja) | N―置換アミド誘導体 | |
US5451606A (en) | Anthraquinone compounds useful to treat osteoarticular conditions, pharmaceutical compositions and method of treatment | |
US5196567A (en) | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same | |
CH628014A5 (en) | Gamma-aryl-gamma-oxoisovaleric acids having antiphlogistic and antalgic properties | |
EP0223647B1 (fr) | Alkylcarboxamides de pyridylalkylamines, leurs préparations et leur utilisation en tant que médicaments | |
JPS61227579A (ja) | ホモシステインチオラクトン誘導体、その製法およびそれを含有する医薬 | |
GB2204579A (en) | Optically active oxo-isoindolinyl derivatives | |
JPS6330462A (ja) | 新規グアニジノメチルベンツアミド誘導体およびそれを有効成分とする抗潰瘍剤 | |
US4766148A (en) | Biphenylylpropionic acid derivative and pharmaceutical composition containing the same | |
FR2544313A1 (fr) | Les n-cycloalcoyl methyl-2 oxo-3 diaryl 5-6 as triazines, leur procede de fabrication et leur utilisation en tant que medicament | |
CN1036267C (zh) | 氨基取代的苯甲酰胍的制备方法 | |
JPH0276882A (ja) | 光学活性ヒダントイン誘導体 | |
US4341773A (en) | 2,4-Diamino-5-sulfamoylbenzene sulfonic acids and process for their manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070914 Year of fee payment: 6 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080914 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090914 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100914 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110914 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |